CAJ | 학술논문

目的评价拉米夫定联合中成药对慢性乙型肝炎(CHB)患者血清HBeAg 的影响.方法按照系统评价的原则制定检索策略,收集符合纳入标准的研究并采集相关信息和Meta分析.结果 52篇文献符合纳入标准;11个联合治疗方案、4121名患者纳入研究,拉米夫定联合苦参素治疗CHB疗程为3个月、6个月、12个月时相对危险度分别为2.45,1.97,1.64,95%可信区间分别为(2.12,2.84),(1.70,2.27),(1.43,1.88),联合组与对照组相比均有统计学意义.结论拉米夫定联合苦参素治疗慢性乙型肝炎血清HBeAg转阴率的疗效有优于单用拉米夫定的趋势.其他联合治疗方案由于样本例数少而无法得出结论.
목적 평개랍미부정연합중성약대만성을형간염(CHB)환자혈청HBeAg 적영향.방법 안조계통평개적원칙제정검색책략,수집부합납입표준적연구병채집상관신식화Meta분석.결과 52편문헌부합납입표준;11개연합치료방안、4121명환자납입연구,랍미부정연합고삼소치료CHB료정위3개월、6개월、12개월시상대위험도분별위2.45,1.97,1.64,95%가신구간분별위(2.12,2.84),(1.70,2.27),(1.43,1.88),연합조여대조조상비균유통계학의의.결론 랍미부정연합고삼소치료만성을형간염혈청HBeAg전음솔적료효유우우단용랍미부정적추세.기타연합치료방안유우양본례수소이무법득출결론.
Objective To estimate the influence of Chinese patent medicines combined with lamivudine on Sero-HBeAg in chronic hepatitis B patiehts.Methods Search strategy was formulated according to the Cochrane systematic review,related information of the literatures met inclusion criteria was gathered.Results 52 trials met the inclusioncriteria,11 sorts of traditional chinese medicine,11 sorts of treatment prescription,4 121 patients were included.Statistical significance between the two groups was identified after treatment for 3 months,6 months,12 months[relative risk 2.45,1.97,1.64,95% confidence interval(2.12,2.84),(1.70,2.27),(1.43,1.88) respectively].Conclusion The therapeutic effect of kushenin combined with lamivudine for chronic hepatitis B on Sero- HBeAg is superior to that of Lamivudine alone.As for other joint programms with only a few samples we could not reach a conclusion.